How Loading Dose Strategies for Depot Paliperidone Can Go Wrong

Area of Science:

• Pharmacology
• Clinical Neurology
• Psychiatry

Background:

• Paliperidone palmitate (Invega Sustenna) is a long-acting injectable antipsychotic.
• Prescribing information often recommends a loading dose strategy for rapid therapeutic effect.

Observation:

• A patient experienced severe and prolonged Parkinsonism after receiving the recommended paliperidone palmitate loading dose.
• This adverse event underscores potential risks associated with standard dosing protocols.

Findings:

• The case demonstrates the critical need for clinicians to exercise caution before strictly adhering to package insert guidelines for paliperidone palmitate loading doses.
• Therapeutic drug monitoring, using serum prolactin levels as a surrogate marker, proved useful in managing the patient's adverse reaction, despite limitations in direct drug level measurement.

Implications:

• Healthcare providers should consider individual patient factors and potential risks before initiating antipsychotic loading doses.
• Therapeutic drug monitoring, even with indirect markers, can be a valuable tool in managing complex patient responses to long-acting injectable antipsychotics.
• Further research into optimizing dosing strategies and monitoring techniques for depot antipsychotics is warranted.